Patents Assigned to Hutchison Medipharma Limited
  • Cycloolefin substituted heteroaromatic compounds and their use
    Patent number: 12234211
    Abstract: Compounds of formula (I) or a pharmaceutically acceptable salt thereof, and/or solvates racemic mixtures, enantiomers, diasteromers, and tautomers thereof, wherein A, R1, R2, R3, R3?, R4, R4?, R5, R6, R7, R8, m, and n are as defined in the detailed description.
    Type: Grant
    Filed: May 18, 2022
    Date of Patent: February 25, 2025
    Assignee: HUTCHISON MEDIPHARMA LIMITED
    Inventors: Wei-Guo Su, Guangxiu Dai, Kun Xiao
  • Crystalline forms of (s)-4-amino-6-((1-(3-chloro-6-phenylimidazo[1,2-b]pyridazine-7-yl)ethyl)amino)pyrimidine-5-carbonitrile as inhibitors of phosphatidylinositol-3-kinase
    Patent number: 12180214
    Abstract: The present invention belongs to the pharmaceutical field, and provides crystalline forms, solvates and the crystalline forms thereof of the compound (S)-4-amino-6-((1-(3-chloro-6-phenylimidazo[1,2-b]pyridazin-7-yl)ethyl)amino)pyrimidine-5-carbonitrile of the formula shown below, and the pharmaceutical compositions comprising the same as well as the methods of preparing the same and the use thereof.
    Type: Grant
    Filed: January 5, 2023
    Date of Patent: December 31, 2024
    Assignee: HUTCHISON MEDIPHARMA LIMITED
    Inventors: Zhenping Wu, Wenji Li, Ling Feng
  • Substituted piperazines as BTK inhibitors
    Patent number: 12173008
    Abstract: The present invention relates to heteroaryl heterocyclic compounds of formula (I), pharmaceutical compositions comprising same, methods for preparing same, and uses thereof, wherein the variables are as defined in the description.
    Type: Grant
    Filed: April 17, 2023
    Date of Patent: December 24, 2024
    Assignee: HUTCHISON MEDIPHARMA LIMITED
    Inventors: Guangxiu Dai, Kun Xiao
  • HETEROARYL HETEROCYCLIC COMPOUNDS AND USES THEREOF
    Publication number: 20240398791
    Abstract: The present invention relates to heteroaryl heterocyclic compounds, e.g., the compound of the formula shown below, pharmaceutical compositions comprising same, methods for preparing same, and uses thereof.
    Type: Application
    Filed: June 27, 2024
    Publication date: December 5, 2024
    Applicant: HUTCHISON MEDIPHARMA LIMITED
    Inventors: Guangxiu DAI, Kun XIAO
  • Method for the manufacture of 3-[(1S)-1-imidazo[1,2-a]pyridin-6-ylethyl]-5-(1-methylpyrazol-4-yl)triazolo[4,5-b]pyrazine and polymorphic forms thereof
    Patent number: 12134613
    Abstract: This specification generally relates to an improved method for the manufacture of 3-[(1S)-1-imidazo[1,2-a]pyridin-6-ylethyl]-5-(1-methylpyrazol-4-yl)triazolo[4,5-b]pyrazine (I), or pharmaceutically acceptable salts thereof; polymorphic forms thereof, and intermediates useful in the manufacture of such compounds and salts thereof.
    Type: Grant
    Filed: September 10, 2019
    Date of Patent: November 5, 2024
    Assignees: AstraZeneca AB, Hutchison Medipharma Limited
    Inventors: Andrew Roy Turner, Andrew Timothy Turner, Gareth Paul Howell, Malcolm Allan Young Gall, Keith Raymond Mulholland, Neil Keith Adlington, Zhenping Tian, Bo Liu, Qisun Gong, Wei Yu
  • ANTI-OX40 ANTIBODY AND USES THEREOF
    Publication number: 20240301077
    Abstract: The present invention provides an anti-OX40 antibody or antigen-binding fragment thereof, a preparation method therefor and the use for treating OX40-related diseases or conditions.
    Type: Application
    Filed: May 22, 2024
    Publication date: September 12, 2024
    Applicant: HUTCHISON MEDIPHARMA LIMITED
    Inventors: Yizhen YANG, Yu CAI, Xiong LI, Lei ZHOU, Weiguo QING, Wei-Guo SU
  • Salts of a compound and the crystalline forms thereof
    Patent number: 12084441
    Abstract: The present invention belongs to the pharmaceutical field, and provides the pharmaceutically acceptable salts of the compound (S)-7-(4-(1-(methylsulfonyl)piperidin-4-yl)phenyl)-N-(morpholin-2-ylmethyl)pyrido[3,4-b]pyrazin-5-amine and the crystalline forms thereof, the solvates and the crystalline forms thereof, the pharmaceutical compositions comprising the same as well as the methods of preparing the same and the use thereof.
    Type: Grant
    Filed: June 21, 2022
    Date of Patent: September 10, 2024
    Assignee: HUTCHISON MEDIPHARMA LIMITED
    Inventors: Zhenping Wu, Wenji Li, Ling Feng
  • Substituted pyridines, pyridazines, pyrimidines, and 1,2,3-triazines as bruton's tyrosine kinase inhibitors
    Patent number: 12070457
    Abstract: The present invention relates to heteroaryl heterocyclic compounds, e.g., the compound of the formula shown below, pharmaceutical compositions comprising same, methods for preparing same, and uses thereof.
    Type: Grant
    Filed: August 31, 2022
    Date of Patent: August 27, 2024
    Assignee: HUTCHISON MEDIPHARMA LIMITED
    Inventors: Guangxiu Dai, Kun Xiao
  • Anti-OX40 antibody and uses thereof
    Patent number: 12030951
    Abstract: The present invention provides an anti-OX40 antibody or antigen-binding fragment thereof, a preparation method therefor and the use for treating OX40-related diseases or conditions.
    Type: Grant
    Filed: August 18, 2022
    Date of Patent: July 9, 2024
    Assignee: HUTCHISON MEDIPHARMA LIMITED
    Inventors: Yizhen Yang, Yu Cai, Xiong Li, Lei Zhou, Weiguo Qing, Wei-Guo Su
  • HETEROAROMATIC COMPOUNDS AND USES THEREOF
    Publication number: 20240092774
    Abstract: Providing heteraromatic compounds and uses thereof. In particular, providing heteraromatic compounds of formula (I), pharmaceutical compositions comprising same, methods for preparing same and uses thereof, wherein the variables are as defined in the description.
    Type: Application
    Filed: September 17, 2021
    Publication date: March 21, 2024
    Applicant: HUTCHISON MEDIPHARMA LIMITED
    Inventors: Wei-Guo SU, Weihan ZHANG, Haibin YANG
  • Certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use therefor
    Patent number: 11896592
    Abstract: Provided are certain triazolopyridines and triazolopyrazines of Formula 1, wherein X, Y, R1, R2, R3, R4 and R5 have any of the meanings described herein; processes for their preparation, pharmaceutical compositions containing them, and their use in the treatment of cell proliferative disorders.
    Type: Grant
    Filed: February 3, 2021
    Date of Patent: February 13, 2024
    Assignee: Hutchison Medipharma Limited
    Inventors: Wei-Guo Su, Hong Jia, Guangxiu Dai
  • Substituted piperazines as BTK inhibitors
    Patent number: 11655254
    Abstract: Provided are heteroaryl heterocyclic compounds of formula (I), pharmaceutical compositions comprising same, methods for preparing same, and uses thereof, wherein the variables are as defined in the description. The compounds are Btk inhibitors.
    Type: Grant
    Filed: April 25, 2022
    Date of Patent: May 23, 2023
    Assignee: HUTCHISON MEDIPHARMA LIMITED
    Inventors: Guangxiu Dai, Kun Xiao
  • Crystalline forms of (S)-4-amino-6-((1-(3-chloro-6-phenylimidazo[1,2-b]pyridazine-7-yl)ethyl)amino)pyrimidine-5-carbonitrile as inhibitors of phosphatidylinositol-3-kinase
    Patent number: 11584750
    Abstract: The present invention belongs to the pharmaceutical field, and provides crystalline forms, solvates and the crystalline forms thereof of the compound (S)-4-amino-6-((1-(3-chloro-6-phenylimidazo[1,2-b]pyridazin-7-yl)ethyl)amino)pyrimidine-5-carbonitrile of the formula shown below, and the pharmaceutical compositions comprising the same as well as the methods of preparing the same and the use thereof.
    Type: Grant
    Filed: April 18, 2019
    Date of Patent: February 21, 2023
    Assignee: HUTCHISON MEDIPHARMA LIMITED
    Inventors: Zhenping Wu, Wenji Li, Ling Feng
  • CYCLOOLEFIN SUBSTITUTED HETEROAROMATIC COMPOUNDS AND THEIR USE
    Publication number: 20220372005
    Abstract: Compounds of formula (I) or a pharmaceutically acceptable salt thereof, and/or solvates racemic mixtures, enantiomers, diasteromers, and tautomers thereof, wherein A, R1, R2, R3, R3?, R4, R4?, R5, R6, R7, R8, m, and n are as defined in the detailed description.
    Type: Application
    Filed: May 18, 2022
    Publication date: November 24, 2022
    Applicant: HUTCHISON MEDIPHARMA LIMITED
    Inventors: Wei-Guo SU, Guangxiu DAI, Kun XIAO
  • 2-(3?-(hydroxymethyl)-1-methyl-5-((5-(2-methyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-yl)amino)-6-oxo-1,6-dihydro-[3,4?-bipyridin]-2?-yl)-7,7-dimethyl-7,8-dihydro-2H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-1(6H)-one as a BTK inhibitor
    Patent number: 11478474
    Abstract: The present invention relates to heteroaryl heterocyclic compounds, e.g., the compound of the formula shown below, pharmaceutical compositions comprising same, methods for preparing same, and uses thereof.
    Type: Grant
    Filed: October 20, 2021
    Date of Patent: October 25, 2022
    Assignee: HUTCHISON MEDIPHARMA LIMITED
    Inventors: Guangxiu Dai, Kun Xiao
  • Cycloolefin substituted heteroaromatic compounds and their use
    Patent number: 11414390
    Abstract: Compounds of formula (I) or a pharmaceutically acceptable salt thereof, and/or solvates, racemic mixtures, enantiomers, diasteromers, and tautomers thereof, wherein A, R1, R2, R3, R3?, R4, R4?, R5, R6, R7, R8, m, and n are as defined in the detailed description.
    Type: Grant
    Filed: September 7, 2018
    Date of Patent: August 16, 2022
    Assignee: Hutchison Medipharma Limited
    Inventors: Wei-Guo Su, Guangxiu Dai, Kun Xiao
  • Salts of a compound and the crystalline forms thereof
    Patent number: 11396507
    Abstract: The present invention belongs to the pharmaceutical field, and provides the pharmaceutically acceptable salts of the compound (S)-7-(4-(1-(methylsulfonyl)piperidin-4-yl)phenyl)-N-(morpholin-2-ylmethyl)pyrido[3,4-b]pyrazin-5-amine and the crystalline forms thereof, the solvates and the crystalline forms thereof, the pharmaceutical compositions comprising the same as well as the methods of preparing the same and the use thereof.
    Type: Grant
    Filed: August 22, 2018
    Date of Patent: July 26, 2022
    Assignee: HUTCHISON MEDIPHARMA LIMITED
    Inventors: Zhenping Wu, Wenji Li, Ling Feng
  • PHARMACEUTICAL PREPARATION OF FRUQUINTINIB AND USE THEREOF
    Publication number: 20220125789
    Abstract: A pharmaceutical composition of fruquintinib comprising filler and its preparing process are disclosed. The filler is selected from starch, microcrystalline cellulose or a combination thereof. The composition is in the form of a tablet or capsule and can be used in the treatment of cancer, such as colorectal cancer, non-small cell lung cancer, and gastric cancer.
    Type: Application
    Filed: November 15, 2019
    Publication date: April 28, 2022
    Applicant: Hutchison Medipharma Limited
    Inventors: Zhongzhou Liu, Jinli Wu, Chongdong Fu
  • CYCLOOLEFIN SUBSTITUTED HETEROAROMATIC COMPOUNDS AND THEIR USE
    Publication number: 20210363115
    Abstract: The present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, and/or solvates, racemic mixtures, enantiomers, diasteromers, and tautomers thereof, wherein A, R1, R2, R3, R3?, R4, R4?, R5, R6, R7, R8, m, and n are as defined in the detailed description of the invention.
    Type: Application
    Filed: September 7, 2018
    Publication date: November 25, 2021
    Applicant: Hutchison Medipharma Limited
    Inventors: Wei-Guo Su, Guangxiu Dai, Kun Xiao
  • Crystalline forms of 6-((6,7-dimethoxyquinazolin-4-yl)oxy)-N,2-dimethylbenzofuran-3-carboxamide
    Patent number: 11046674
    Abstract: Crystalline forms of compound 6-(6,7-dimethoxyquinazolin-4-yloxy)-N,2-dimethylbenzofuran-3-carboxamide, pharmaceutical compositions and the methods of preparation and the use thereof.
    Type: Grant
    Filed: November 8, 2019
    Date of Patent: June 29, 2021
    Assignee: HUTCHISON MEDIPHARMA LIMITED
    Inventors: Zhenping Wu, Wenji Li, Yuping Chu